All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-02-08T11:00:34.000Z

What exciting updates on maintenance therapy in AML were presented at ASH 2023?

Feb 8, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in AML

At the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, Gail Roboz, Weill Cornell Medicine, New York, US, shared her insights with the AML Hub. We asked “What exciting updates on maintenance therapy in acute myeloid leukemia were presented at ASH 2023?”

What exciting updates on maintenance therapy in acute myeloid leukemia were presented at ASH 2023?

Roboz discusses the use of oral azacitidine as a maintenance therapy for patients with acute myeloid leukemia, highlighting results from the QUAZAR AML-001 trial, before exploring the impact of maintenance therapy on measurable residual disease status and postremission outcomes. She reviews the optimal selection of maintenance therapies, and how measurable residual disease status can influence treatment decisions in subgroups such as NPM1-mutated and FLT3-mutated AML. Roboz concludes by emphasizing the need for more randomized clinical trials evaluating maintenance therapies and considers future directions, including menin inhibitors and high-sensitivity measurable residual disease testing.

Newsletter

Subscribe to get the best content related to AML delivered to your inbox